Research programme: mTOR/PI3K inhibitors - RocheAlternative Names: PI-103
Latest Information Update: 09 Sep 2013
At a glance
- Originator The Institute of Cancer Research
- Class Pyrimidines
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer